Encorafenib plus cetuximab not recommended for previously treated colorectal cancer

Although it meets NICE’s criteria for being a life-extending treatment, the cost-effectiveness estimates are higher than what is normally considered a cost-effective use of NHS resources.

Please sign in or register for FREE

No comments yet.